Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has sold all its Solabegron assets to a clinical development company AltheRx Pharmaceuticals.
Subscribe to our email newsletter
GSK claims Solabegron is a highly selective and potent beta3-adrenoceptor agonist which is in development for the reduction of symptoms of overactive bladder (OAB) and irritable bowel syndrome (IBS).
In a Phase II trial, Solabegron has showed positive results and demonstrated tolerability profile in the treatment of OAB in women and IBS.
AltheRx CEO Shawn O’Brien said Solabegron is a primary product for AltheRx and clinical data suggest that the novel mechanism of Solabegron has the potential to address the needs of patients suffering from OAB and IBS.
AltheRx chief scientific officer Eliot Ohlstein said they are currently planning to advance the OAB clinical development program for Solabegron into Phase III later this year.